Hemophilia B Clinical Trial
— Hémophilie BOfficial title:
Discrepancy Between Factor IX Level and Bleeding Phenotype
| NCT number | NCT03946384 |
| Other study ID # | BOVET 2019 |
| Secondary ID | |
| Status | Not yet recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | June 2019 |
| Est. completion date | October 2019 |
It appears that the mutation p.Ile112Thr in the factor IX gene confers a discrepancy between mild factor IX level and severe bleeding phenotype. Databases and litterature analysis are poor on this matter. The goal of this study is to compile bleeding phenotype in patients with this specific mutation to prove the clinico-biological discordance in order to improve patient care and follow-up.
| Status | Not yet recruiting |
| Enrollment | 12 |
| Est. completion date | October 2019 |
| Est. primary completion date | October 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - hemophilia B with p.Ile112Thr mutation on factor IX gene Exclusion Criteria: None |
| Country | Name | City | State |
|---|---|---|---|
| France | CHU Dijon Bourgogne | Dijon |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Universitaire Dijon |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Bleeding phenotype | bleeding phenotype in patients with p.Ile112Thr in factor IX gene | Through study completion, an average of 4 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04072237 -
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
|
Phase 1 | |
| Completed |
NCT02199717 -
An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
|
N/A | |
| Completed |
NCT01662531 -
A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B
|
Phase 3 | |
| Completed |
NCT01335061 -
Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B
|
Phase 3 | |
| Completed |
NCT01217255 -
Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
|
||
| Completed |
NCT00037557 -
Study Evaluating rFIX; BeneFIX in Severe Hemophilia B
|
Phase 3 | |
| Completed |
NCT02554773 -
An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B
|
Phase 1/Phase 2 | |
| Terminated |
NCT02807753 -
The Hemophilia Ultrasound Project
|
||
| Active, not recruiting |
NCT03901755 -
An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
|
||
| Not yet recruiting |
NCT05980377 -
Patterns of Hemophilia Care in Assiut Children Patients
|
||
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Terminated |
NCT03248141 -
Understanding Hemophilia A and B Drug Dosage Administration Patterns
|
||
| Terminated |
NCT01460147 -
Osteoporosis and MRI Study in Hemophilia
|
N/A | |
| Completed |
NCT03818529 -
ATHN 8: Previously Untreated Patients (PUPs) Matter Study
|
||
| Completed |
NCT02571569 -
A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
|
Phase 1 | |
| Terminated |
NCT01620801 -
Hemophilia B Gene Therapy With AAV8 Vector
|
Phase 1 | |
| Completed |
NCT01233440 -
Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B
|
Phase 1 | |
| Active, not recruiting |
NCT04135300 -
Gene Therapy for Chinese Hemophilia B
|
N/A | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Terminated |
NCT00947193 -
Study of Ataluren (PTC124) in Hemophilia A and B
|
Phase 2 |